CompletedPhase 2NCT00901147
Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma
Studying Anaplastic large cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Singapore General Hospital
- Principal Investigator
- Yeow Tee Goh, MBBS MMedSingapore General Hospital
- Intervention
- panobinostat and bortezomib(drug)
- Enrollment
- 25 enrolled
- Eligibility
- 21 years · All sexes
- Timeline
- 2009 – 2014
Study locations (5)
- Hospital Universiti Kebangsaan Malaysia ( HUKM ), Kuala Lumpur, Kuala Lumpur, Malaysia
- Subang Jaya Medical Centre, Subang Jaya, Selangor, Malaysia
- National Cancer Center, Singapore, Singapore
- Singapore General Hospital, Singapore, Singapore
- Samsung Medical Centre, Seoul, Seoul, South Korea
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00901147 on ClinicalTrials.govOther trials for Anaplastic large cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06561048Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaCorvus Pharmaceuticals, Inc.
- RECRUITINGPHASE1NCT06494371A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell LymphomaRuijin Hospital
- RECRUITINGPHASE1, PHASE2NCT06137144AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.AstraZeneca
- ACTIVE NOT RECRUITINGPHASE1NCT04526834Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin LymphomaTessa Therapeutics
- ACTIVE NOT RECRUITINGPHASE3NCT04881838CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCLChildren's Cancer Group, China
- ACTIVE NOT RECRUITINGPHASE2NCT02978625Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersNational Cancer Institute (NCI)
- RECRUITINGNCT04220970Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) RegistryThe Lymphoma Academic Research Organisation